Navigation Links
Victhom Announces Launch of Enhanced Company Website
Date:1/9/2009

QUEBEC, Jan. 9 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., "Victhom" (TSX: VHB), today announced the unveiling of its updated corporate Website at www.victhom.com. The Website features a new structure that highlights advances in the Company's two operating divisions; Neurobionix, which is developing an implantable neurostimulation device for gait disorders, and Biotronix, which is developing and manufacturing computerized prostheses for above-knee amputees.

Commenting on the new Website, Normand Rivard, Acting President and Chief Financial Officer, stated: "The new layout provides users with more intuitive navigation, enhanced visual content and a comprehensive view of the Company's technologies and products". He went on to say, "This redesigned Website affirms our commitment to provide relevant information and educate all of our stakeholders including patients, medical professionals, investors, and current and future business partners".

The Neurobionix division portion of the Website includes a new "Patient section" that provides information on the impact of cerebral stroke and a particular aspect of gait disorder known as foot drop. This section presents contemporary treatment options for foot drop sufferers as well as the emerging use of neurostimulation devices that provide instantaneous assistance to patients.

A new "Medical Professional section" has been added and designed for use by members of the professional medical community. This section provides medical and technical information on the Company's proprietary implantable assistive device known as Neurostep(R), which is currently in clinical trials and designed to restore mobility to persons suffering from foot drop. Information about the product includes a new animation video demonstrating various aspects of the Neurostep(R) System as well as updates regarding the Company's clinical activities.

The Biotronix
'/>"/>

SOURCE VICTHOM HUMAN BIONICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
2. Victhom to Participate in the OneMedPlace Finance Forum
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)...  Moerae Matrix Inc. announced today the initiation ... MMI-0100, a first-in-class inhibitor of MAPKAP kinase 2 ... characterized by inflammation and fibrosis.  The study, conducted ... is a double-blind, two-way cross-over design lipopolysaccharide (LPS) ... of MMI-0100 when given via inhalation to healthy ...
(Date:7/28/2015)... 28, 2015 CSL Behring announced ... accepted for review the company,s Biologics License Application (BLA) ... for the treatment of hemophilia A. In the pivotal ... Hemophilia A is a congenital bleeding ... all affected patients are male. People with hemophilia A ...
(Date:7/28/2015)... Md. and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 ... today announced its financial results for the second ...  sales grew nearly 300% as compared to the ... first launched," said Roger Jeffs, Ph.D., United Therapeutics, ... Orenitram sales was due to an increase in ...
(Date:7/28/2015)... , July 28, 2015  Faced with ... that are palliative rather than symptomatic, the global ... few existing therapies capable of curing or significantly ... are starting to look towards regenerative medicine as ... a new paradigm in human health with the ...
Breaking Biology Technology:Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5
... (Nasdaq: ONXX ) today announced that it ... January 30, at 8:30,a.m. Eastern Time. Interested parties ... http://www.wsw.com/webcast/wa48/onxx/ , It is recommended ... order to,register and download any necessary software. For ...
... Inc.,(NYSE: FRX ), Forest Laboratories Holdings, Ltd., ... GmbH announced that they have filed a second,lawsuit ... of Delaware against,additional companies for infringement of U.S. ... Forest,s Namenda(R) product. The defendants,named in the lawsuit ...
... CENTREVILLE, Va., Jan. 25 Octapharma is ... member of the Biotechnology Industry,Organization. Membership in ... is the Association,s considerable influence on the ... some of the,largest and most research intensive ...
Cached Biology Technology:Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement 2Octapharma Joins Biotechnology Industry Organization 2
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/2/2015)... 25, 2015 Research ... of the "Natural Language Processing Market by ... OCR, Pattern & Image Recognition) - Worldwide Forecast ... The key vendors occupying the market are ... Microsoft Corporation, NetBase Solutions, SAS Institute Inc., Verint ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... R.I. [Brown University] Any parent knows that newborns still ... fully acute vision. In a wide variety of nascent animals, ... then leave it to the developing nervous system to do ... provide new evidence of a role for exposure to light ...
... of the story of muscle development, Johns Hopkins researchers ... builds finger-like projections that invade into another muscle cell,s ... muscle cell fusion, the researchers say, is not only ... regeneration after injury or disease. The work, they believe, ...
... based in the Faculty of Medicine & Dentistry at ... handed out by the Canadian Society of Chemistry for ... Li and Jonathan Martin, faculty members of the Division ... Laboratory Medicine & Pathology, have all been recognized by ...
Cached Biology News:Early light refines the brain's circuitry for vision 2Early light refines the brain's circuitry for vision 3Early light refines the brain's circuitry for vision 4How muscle develops: A dance of cellular skeletons 2How muscle develops: A dance of cellular skeletons 3U of Alberta research group recognized with national chemistry awards 2
WTAP Antibody...
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
Biology Products: